Bangladesh Pharmaceutical Industry Analysis

On November 24, 2026, Bangladesh loses the WTO TRIPS pharmaceutical waiver that lets local firms formulate patented molecules without licences. The waiver runs to end-2033, but only for countries that stay LDCs: graduation forfeits it. The exposed slice is narrow but high-value, the roughly one-fifth of the domestic pipeline that is patented (PRI, 2020), and the binding move is not the API Park or new R&D but a graduating-LDC extension request lodged at the WTO before graduation, citing the Maldives public-health precedent. Everything else is a multi-year build the extension buys time to finish.

Bangladesh's pharmaceutical industry is a manufacturing success built on a legal exemption. EPB data put exports at $213.16 million in FY25 across 166 countries, more than double the $103.46 million of FY18, on a sector that supplies about 98% of a roughly $3.5 billion domestic market. That edge rests on the WTO TRIPS LDC waiver, which lets local firms formulate patented molecules without licences. On November 24, 2026, graduation removes it. The single highest-value policy move is to secure a post-graduation extension; everything else (API capacity, R&D, WHO prequalification) is a multi-year build that the extension buys time to complete.

What graduation changes

The LDC pharmaceutical waiver runs to end-2033, but only for countries that remain LDCs. The trap is that graduation, not the calendar, ends it: Bangladesh forfeits the waiver on November 24, 2026, seven years before the nominal sunset. From that date the patented slice of the pipeline, about 20% of drugs made here versus 80% generic (PRI, 2020), can no longer be freely copied; new launches need patent clearance, licensing, or compulsory licensing. CPD's health-budget analysis states the consequence plainly: unless Bangladesh secures an extension of the transition period after it graduates in 2026, the waiver will be withdrawn (CPD, Health Budget of Bangladesh). The Dhaka Chamber flagged the same cliff in its 2022 annual report, naming the post-2026 risk to the sector directly (DCCI Annual Report 2022).

There is a usable precedent. The TRIPS Council granted Maldives an extension on public-health grounds, which Bangladesh can cite to make a "duly motivated request"

for graduating LDCs (Bangladesh Enterprise Institute, Navigating New Waters: LDC Graduation and Exports). Bangladesh has filed for a 3-year graduation deferral and is separately lobbying to extend the pharmaceutical waiver to 2029.

API dependency: the cost cliff behind the patent cliff

Even with the waiver extended, the sector imports more than 85% of its Active Pharmaceutical Ingredients, mainly from China and India, at an annual bill of about $1.3 to $1.5 billion (The Daily Star, 2025). The 2020-2021 supply shock showed how fast that exposure converts to production risk. Two levers are now in play. The FY2026-27 budget grants full duty exemption on 51 new API raw materials to push local production (NBR Budget Speech FY2026-27). Against that, the flagship API Park in Munshiganj has a long record of slippage: CPD's macroeconomic reviews repeatedly noted that establishment of the API Park was "inordinately delayed" against its original end-2011 timeline (CPD, Bangladesh Economy Interim Reviews). Treating "behind schedule" as a dated fact, not an assertion: the park has missed its deadline by more than a decade of budget cycles. Post-graduation, USD-denominated API imports compound the risk whenever the taka depreciates and a licensing premium is layered on top.

Quality access is the export ceiling

WHO prequalification, not price, caps Bangladesh's reach into the highest-value markets. PQ products open UN and donor procurement (UNICEF, Global Fund, USAID programmes) and ease regulated-market dossier acceptance. Today Bangladesh holds only a small number of prequalified products, with Beximco's lamivudine tablet among the first to clear the WHO programme. The price advantage that drove exports to 166 countries is exactly what erodes if patent and quality barriers rise together after graduation: the same labour-cost edge competes against India and China in the shrinking unregulated tier.

Recommendations

1. **Ministry of Commerce and the WTO mission file the TRIPS extension request now, citing the Maldives precedent.** The ask is a graduating-LDC pharmaceutical waiver to 2029, lodged before the November 24, 2026 graduation date. Owner: Commerce Secretary plus the Geneva mission. Expected effect: patent-free formulation of the patented ~20% of the pipeline is preserved while capability builds. Success signal: a TRIPS Council decision text granting graduating LDCs an extension before graduation day.

1. Cabinet sets a dated API Park delivery milestone and publishes it. The park has slipped from its end-2011 deadline for over a decade. Owner: Ministry of Industries. Expected effect: open-ended "underway" language is replaced by a public count of operational units and a target year. Success signal: a verified operational-unit count reported each budget cycle against the published target.

1. DGDA runs a WHO prequalification push tied to donor procurement. Co-finance bioequivalence studies and dossier preparation for the leading exporters. Owner: DGDA with BAPI. Expected effect: prequalified products multiply from today's small base, converting the 166-country reach into access to UNICEF and Global Fund tenders that survive graduation. Success signal: a year-on-year rise in the count of Bangladesh products listed in the WHO PQ database.

1. **NBR keeps API inputs zero-rated and holds the line on the 2.4% VAT on local medicine trade.** The FY2026-27 budget already exempts duty on 51 API raw materials; CPD has urged zeroing import taxes on API and warns against the 2.4% VAT on locally traded medicines in view of graduation (CPD, Health Budget of Bangladesh). Owner: NBR. Expected effect: the input cost base is held down while the patent and API transitions land. Success signal: no net increase in the landed tax on API or finished medicine through the transition window.

What would change this view

If the WTO declines a graduating-LDC pharmaceutical extension despite the Maldives precedent, the timeline collapses and the priority shifts from buying time to emergency licensing and import sourcing for the patented ~20%. If the API Park posts verified operational units against a published milestone, the API-dependency risk downgrades from structural to managed. And if export earnings continue past the $213.16 million FY25 mark into regulated markets via WHO PQ, the quality ceiling, not the patent cliff, becomes the binding constraint.

Sources: EPB (Export Promotion Bureau); DGDA (Directorate General of Drug Administration); World Bank (2024); DCCI Annual Report 2022 and 2023; PRI (Policy Research Institute), WP25 2020; WHO Prequalification Programme; WTO TRIPS Council; UN Committee for Development Policy; CPD (Health Budget of Bangladesh, Bangladesh Economy Interim Reviews); NBR Budget Speech FY2026-27; Bangladesh Enterprise Institute, Navigating New Waters; The Daily Star.

Export earnings and destination counts from EPB monthly statements (FY25), cross-checked against The Daily Star reporting of EPB data. Domestic market size from DCCI Annual Report 2023; domestic-demand share from the World Bank (2024). Generic-versus-patented split from PRI WP25 (2020). API import dependence and the import bill from The Daily Star (2025) and DGDA. FY2026-27 fiscal measures from the NBR Budget Speech. WHO prequalification status from the WHO Prequalification public database. TRIPS waiver timeline from WTO documents and the UN CDP graduation decision. Analysis by BDPolicyLab.